Amdoxovir
 |
| Systematic (IUPAC) name |
| [(2R,4R)-4-(2,6-Diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol |
| Clinical data |
| Pregnancy cat. |
? |
| Legal status |
? |
| Identifiers |
| CAS number |
145514-04-1  Y |
| ATC code |
None |
| PubChem |
CID 124088 |
| ChemSpider |
110576 Y |
| UNII |
54I81H0M9C Y |
| KEGG |
D02890 Y |
| ChEMBL |
CHEMBL458876 Y |
| NIAID ChemDB |
005431 |
| Chemical data |
| Formula |
C9H12N6O3 |
| Mol. mass |
252.23 g/mol |
- n2c1c(nc(nc1n(c2)[C@@H]3O[C@@H](OC3)CO)N)N
|
-
InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1 Y
Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N Y
|
 Y (what is this?) (verify)
|
Amdoxovir is a nucleoside reverse transcriptase inhibitor (NRTI) undergoing research for the treatment of HIV. It was discovered by R.F. Schinazi (Emory University) and C.K. Chu (University of Georgia). It is being developed by RFS Pharma.[1] Currently, it is in Phase II clinical studies.
References [edit]
External links [edit]
Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF (2010). "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther 15 (2): 185–192. doi:10.3851/IMP1514. PMID 20386073.
(what is this?) (verify)
